GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Fractyl Health Inc.
Shares of Fractyl Health, a company developing a therapy for type 2 diabetes, reflect the potential of its innovative approach. The price chart is a story driven by expectations for clinical trial results in a massive market.
Share prices of companies in the market segment - Pharma metabolism
Fractyl Health develops new approaches to treating metabolic diseases such as type 2 diabetes and obesity, including procedural therapies to restore gut health and gene therapy. We've classified it in the "Pharma Metabolism" segment. The chart below shows the overall dynamics of the sector, which is seeking breakthrough methods to combat the obesity pandemic.
Broad Market Index - GURU.Markets
Fractyl Health is a healthcare company developing innovative treatments for metabolic diseases like type 2 diabetes by targeting the gut. Its breakthrough approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Fractyl compares to it.
Change in the price of a company, segment, and market as a whole per day
GUTS - Daily change in the company's share price Fractyl Health Inc.
For Fractyl Health, Inc., a company developing a type 2 diabetes therapy, daily price change is a measure of its enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to biotech risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
For Fractyl Health, Inc., a company developing a type 2 diabetes therapy, daily price change is a measure of its enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to biotech risk assessment formulas.
Daily change in the price of a broad market stock, index - GURU.Markets
Fractyl Health develops innovative treatments for metabolic diseases such as type 2 diabetes. This represents a huge market and a major medical problem. The company's stock price fluctuates, reflecting progress in the fight against these diseases, and this vital pulse on the health of millions of people contributes to the overall market dynamics visible on the chart.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Fractyl Health Inc.
Fractyl Health, Inc.'s year-over-year performance is a story of developing a new approach to treating type 2 diabetes. Its 12-month profitability depends entirely on clinical trial data for its procedure aimed at restoring the duodenal mucosa. Success could offer patients a new, drug-free way to manage the disease.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Fractyl Health, Inc. is a healthcare company developing a new approach to treating metabolic diseases such as type 2 diabetes by targeting the gut. Its stock price is highly volatile, reflecting investor confidence in its breakthrough potential and clinical trial results.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Fractyl, with its type 2 diabetes therapy, is a high-risk, high-potential story. Its stock price since its IPO has been entirely dependent on clinical trial results. The chart isn't about economics, but rather whether investors believe its revolutionary approach will become a reality.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Fractyl Health Inc.
Fractyl Health develops innovative treatments for metabolic diseases such as type 2 diabetes. Its monthly growth is driven by progress in its clinical trials. Data demonstrating the effectiveness of its gene and procedural therapies are the primary drivers.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Fractyl Health is developing new approaches to treating metabolic diseases, such as type 2 diabetes, by targeting the root causes of the disease in the gut. This is a breakthrough, but risky concept. The biotech sector's timeline will reflect the overall interest in new diabetes treatments, providing a backdrop for assessing the potential of Fractyl's innovative therapies.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Fractyl Health develops innovative treatments for type 2 diabetes. As a company at the intersection of biotech and medical devices, its stock is preoccupied with the results of clinical trials. Its stock price is completely disconnected from market cycles and reflects investors' faith in the potential of its technology to transform the treatment of the disease.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Fractyl Health Inc.
Fractyl Health, a company developing therapies for metabolic diseases such as type 2 diabetes, is experiencing high volatility. Weekly stock performance is driven by news of clinical trials of its innovative approach, reflecting the potential for breakthroughs in the treatment of common ailments.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Fractyl Health develops new approaches to treating metabolic diseases such as type 2 diabetes. This chart compares its volatile, data-driven performance with broader trends in the pharmaceutical sector to understand how much investors believe in its revolutionary treatment approach.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Fractyl Health is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that GUTS's performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
GUTS - Market capitalization of the company Fractyl Health Inc.
Fractyl Health's chart is a financial map of a new approach to treating type 2 diabetes. The company's market cap reflects the hopes for its procedure, which aims to restore the intestinal lining. Its dynamics are a barometer of progress in clinical trials and the belief that its method could become an alternative to medication.
GUTS - Share of the company's market capitalization Fractyl Health Inc. within the market segment - Pharma metabolism
Fractyl Health's stake in the pharmaceutical sector is a bet on a new approach to treating metabolic diseases such as type 2 diabetes. The company is developing a procedural therapy that targets the root cause of the disease in the gut. Its size reflects the potential of this breakthrough method.
Market capitalization of the market segment - Pharma metabolism
Fractyl Health develops new approaches to treating metabolic diseases such as type 2 diabetes. The chart below shows the total market capitalization of the entire biotech sector. Its dynamics reflect the enormous investor interest in finding breakthrough treatments for these global epidemics.
Market capitalization of all companies included in a broad market index - GURU.Markets
Fractyl Health develops new approaches to treating metabolic diseases, such as type 2 diabetes, by targeting the duodenum. Its market capitalization is a bet on this breakthrough. The chart below shows the economic weight of companies changing treatment paradigms.
Book value capitalization of the company, segment and market as a whole
GUTS - Book value capitalization of the company Fractyl Health Inc.
For Fractyl Health, book value is its capital and R&D equipment. The chart below shows the financial resources for its breakthrough diabetes therapy. This level is an indicator of its ability to fund clinical trials and commercialize its unique approach.
GUTS - Share of the company's book capitalization Fractyl Health Inc. within the market segment - Pharma metabolism
Fractyl Health is developing a therapy for the treatment of type 2 diabetes. Its value lies in its scientific platform and clinical trial data. The company's tangible asset share will be minimal, typical for an R&D company whose primary capital is intellectual property.
Market segment balance sheet capitalization - Pharma metabolism
Fractyl Health is a company developing a new therapy for type 2 diabetes. Its value lies in its unique procedure and devices, and its tangible assets are its R&D centers and production lines. This is a capital-intensive R&D business. The graph illustrates how dependent the entire medical technology industry is on investment in innovation.
Book value of all companies included in the broad market index - GURU.Markets
Fractyl Health's balance sheet represents capital invested in the development of a breakthrough procedure for treating type 2 diabetes by targeting the duodenal mucosa. The company's assets represent the hope of creating a therapy that can alter the course of the disease, not just control symptoms.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Fractyl Health Inc.
Fractyl Health is developing breakthrough therapies for type 2 diabetes and obesity. Its market capitalization is a pure bet on its unique approach, which targets the root of the problem in the gut. The chart shows how the market values its potential to change the treatment paradigm for these metabolic diseases.
Market to book capitalization ratio in a market segment - Pharma metabolism
Fractyl Health is a medical technology company developing treatments for metabolic diseases such as type 2 diabetes. Its value lies in its innovative approach. The chart shows how much its market valuation exceeds its tangible assets, reflecting its belief in its scientific breakthroughs.
Market to book capitalization ratio for the market as a whole
Fractyl Health is developing new approaches to treating type 2 diabetes and obesity. The chart shows how the market values this potentially revolutionary treatment for metabolic diseases. The company's market capitalization is a bet on the success of its clinical trials, which could offer an alternative to lifelong medication.
Debts of the company, segment and market as a whole
GUTS - Company debts Fractyl Health Inc.
Fractyl Health develops innovative treatments for type 2 diabetes and obesity. For a company bringing a breakthrough medical procedure to market, debt can be used to fund clinical trials and build commercial infrastructure, as this chart illustrates.
Market segment debts - Pharma metabolism
Fractyl Health is developing new approaches to treating metabolic diseases like type 2 diabetes by targeting the root causes in the gut. This is a breakthrough concept. The chart illustrates the general biotech landscape, against which Fractyl is raising capital to clinically test its innovative therapy, which could change the paradigm of diabetes treatment.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Fractyl Health Inc.
Fractyl Health is developing innovative treatments for type 2 diabetes and obesity by addressing the underlying causes of these conditions. This potentially revolutionary approach requires extensive clinical research. This chart shows how the company is funding its expensive research, allowing us to assess its financial risks in achieving a new standard of care.
Market segment debt to market segment book capitalization - Pharma metabolism
Developing treatments for type 2 diabetes and obesity, like Fractyl Health's, addresses one of the biggest global health challenges. This chart shows how the biotech sector funds its innovations. It allows one to assess how capital-intensive the company's procedural therapies are compared to traditional diabetes medications.
Debt to book value of all companies in the market
Fractyl Health develops innovative treatments for type 2 diabetes. Combating such a widespread disease requires large-scale and expensive clinical trials. This chart shows how their debt burden to finance these trials aligns with market norms.
P/E of the company, segment and market as a whole
P/E - Fractyl Health Inc.
This chart for Fractyl Health, Inc., a company developing new approaches to treating type 2 diabetes and obesity, shows its market valuation. The metric reflects investor confidence in its procedural therapies, which target the underlying causes of metabolic diseases.
P/E of the market segment - Pharma metabolism
This indicator represents the average valuation for the biotech sector in which Fractyl Health operates. It reflects the overall level of hope and expectation in the field of metabolic disease treatment. The chart serves as a barometer of investor confidence in new approaches to treating diabetes.
P/E of the market as a whole
Fractyl Health is developing new approaches to treating metabolic diseases like type 2 diabetes by targeting the root causes of the disease in the gut. This breakthrough, yet still experimental, concept is groundbreaking. This chart shows biotech sentiment. It helps us understand whether the market believes Fractyl can change the paradigm of diabetes treatment and the level of risk they are factoring into its valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Fractyl Health Inc.
Fractyl Health develops new approaches to treating metabolic diseases, such as type 2 diabetes, by targeting the underlying causes in the duodenum. The company's future depends on the success of its procedural therapy. This chart shows investor expectations for its revolutionary approach, which could offer an alternative to lifelong medication.
%20P%2FE%20Fractyl%20Health%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Fractyl-Health-Inc.&v=1772664679858 "Chart of the company's future (projected) P/E Fractyl Health Inc.")
Future (projected) P/E of the market segment - Pharma metabolism
Fractyl Health is developing new approaches to treating metabolic diseases such as type 2 diabetes. The company targets the root cause of the disease in the duodenum. This is a revolutionary but risky approach. The chart reflects expectations for the biotech sector, helping to assess the market's confidence in this new scientific paradigm.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772664679905 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Fractyl Health develops innovative treatments for metabolic diseases, such as type 2 diabetes, by targeting the root causes of the disease in the gut. This chart of overall expectations reflects investor sentiment toward breakthrough medical technologies. Market optimism facilitates funding for the development of new approaches to treating the world's most prevalent diseases.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772664679996 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Fractyl Health Inc.
Fractyl Health develops new approaches to treating metabolic diseases such as type 2 diabetes by targeting the root cause of the problem in the gut. This chart shows the cost of developing a breakthrough therapy. Revenue depends on the success of clinical trials and approval of its procedural therapy, which could change the paradigm of diabetes treatment.
Profit of companies in the market segment - Pharma metabolism
Envoy Medical, Inc. develops implantable hearing aids. Profitability depends on the acceptance of this technology as an alternative to traditional devices. This chart illustrates how innovations in medical technology can dramatically improve quality of life, but commercial success depends on convincing physicians, patients, and insurers of the benefits of this new approach.
Overall market profit
Fractyl Health is developing a pancreas-targeted gene therapy for the treatment of type 2 diabetes. The company aims to offer a solution that can address the underlying cause of the disease. Its success depends on the results of clinical trials, which could revolutionize the treatment of one of the most common diseases in the world.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Fractyl Health Inc.
Fractyl Health is a company developing new approaches to treating metabolic diseases, such as type 2 diabetes, by targeting the underlying causes in the duodenum. Its revenue forecast hinges on the success of its procedural treatments. This chart shows analyst expectations for its revolutionary approach to diabetes.
%20profit%20of%20the%20company%20Fractyl%20Health%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Fractyl-Health-Inc.&v=1772664680315 "Graph of future (projected) profit of the company Fractyl Health Inc.")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Fractyl Health develops new approaches to treating metabolic diseases such as type 2 diabetes by targeting their root cause in the gut. The company offers procedural therapies to restore health. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the potential for breakthrough, non-drug treatments for chronic metabolic disorders.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772664680336 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Fractyl Health develops treatments for metabolic diseases such as type 2 diabetes based on novel approaches to duodenal rejuvenation. The company's success depends on clinical results. This revenue forecast schedule impacts the overall investment climate and investor willingness to fund breakthrough medical technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772664680379 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Fractyl Health Inc.
Fractyl Health is a company developing new approaches to treating metabolic diseases such as type 2 diabetes by targeting the underlying causes in the duodenum. The chart reflects investor sentiment for its breakthrough, yet unproven, therapeutic strategy.
P/S market segment - Pharma metabolism
Fractyl Health, Inc. is a metabolic therapeutics company developing novel treatments for type 2 diabetes and obesity that target the root causes of disease in the gut. This chart shows the average valuation for the sector, providing insight into the market's perception of the revenue potential of Fractyl's breakthrough approaches to treating metabolic disorders.
P/S of the market as a whole
Fractyl Health develops new approaches to treating type 2 diabetes and obesity based on procedural interventions in the duodenum to restore metabolic health. This chart, showing average valuations, clearly highlights the gap between the valuations of traditional businesses and companies offering breakthrough treatments for chronic diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Fractyl Health Inc.
Fractyl Health develops innovative treatments for metabolic diseases, particularly type 2 diabetes, by targeting the underlying causes in the duodenum. This chart reflects investors' confidence in the future success of this revolutionary approach. The valuation is based on the expected revenue from its treatments if they are widely adopted.
%20P%2FS%20Fractyl%20Health%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Fractyl-Health-Inc.&v=1772664680522 "The graph of the company's future (projected) P/S Fractyl Health Inc.")
Future (projected) P/S of the market segment - Pharma metabolism
Fractyl Health develops innovative treatments for metabolic diseases such as type 2 diabetes and obesity. Its procedure aims to restore duodenal function. The chart shows how investors estimate Fractyl's future sales, reflecting the potential of its breakthrough approach to chronic disease treatment.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772664680553 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Future revenue forecasts in biotech depend on new approaches to treating chronic diseases such as type 2 diabetes. Fractyl Health is developing a procedure aimed at restoring the intestinal lining to improve metabolic health. Their innovative approach offers hope for new, non-drug treatments to combat this global epidemic.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772664680599 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Fractyl Health Inc.
Fractyl Health is a company developing innovative treatments for metabolic diseases such as type 2 diabetes. While in clinical trials, the company does not yet have commercial sales revenue. This chart reflects its investor-funded research and development (R&D) pending approval of its therapeutics.
Sales of companies in the market segment - Pharma metabolism
Fractyl Health develops innovative treatments for metabolic diseases, such as type 2 diabetes, based on the duodenal mucosa. This chart shows total revenue in the metabolism-focused pharmaceutical segment. It illustrates the search for fundamentally new approaches to treating chronic diseases by targeting the underlying cause.
Overall market sales
Fractyl Health is a metabolic therapeutics company developing procedures to alter duodenal function to treat type 2 diabetes and obesity. This is a new approach to treating chronic diseases. Success depends on clinical data. This trend in the overall economic climate influences funding for innovative medical procedures and devices.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Fractyl Health Inc.
Fractyl Health is developing breakthrough treatments for type 2 diabetes and obesity based on procedural interventions targeting the duodenal mucosa. The company's future depends on the success of its clinical trials. The chart shows analysts' speculative forecasts, which are betting on a new non-drug approach to treating metabolic diseases.
%20sales%20of%20the%20company%20Fractyl%20Health%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Fractyl-Health-Inc.&v=1772664680630 "Schedule of future (projected) sales of the company Fractyl Health Inc.")
Future (projected) sales of companies in the market segment - Pharma metabolism
Fractyl Health develops innovative treatments for metabolic diseases, particularly type 2 diabetes. The company offers procedural therapy aimed at restoring duodenal function. This chart displays projected sales for the entire metabolism-related pharmaceutical segment, highlighting expectations for the diabetes treatment market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772664680641 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Fractyl Health develops new approaches to treating metabolic diseases, such as type 2 diabetes, by targeting the underlying causes in the gut. The company's success depends on clinical trials and the acceptance of its methods. This overall economic activity schedule impacts healthcare system budgets, which determine how quickly new therapeutic approaches are implemented.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772664680665 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Fractyl Health Inc.
Fractyl Health develops new approaches to treating metabolic diseases such as type 2 diabetes. This indicator reflects the financial trajectory of an innovative company. It demonstrates the investment in clinical trials required to bring its unique procedure to market and achieve commercial success in medicine.
Market segment marginality - Pharma metabolism
Fractyl Health is a metabolic therapeutics company developing treatments for type 2 diabetes and obesity. Profitability will depend on the commercialization of its innovative approaches. This metric reflects the company's operational structure at the clinical development stage compared to other companies in the field.
Market marginality as a whole
Fractyl Health is a metabolic therapeutics company developing treatments for type 2 diabetes and obesity by targeting the duodenal mucosa. Their approach is groundbreaking. The company's success depends on clinical trials. This overall profitability schedule does not affect their scientific activities.
Employees in the company, segment and market as a whole
Number of employees in the company Fractyl Health Inc.
Fractyl Health develops innovative treatments for metabolic diseases such as type 2 diabetes, including gene therapy and medical devices. This chart shows the company's growth in the clinical stage. The expansion of its team of scientists and clinicians reflects progress in testing its comprehensive therapeutic approaches.
Share of the company's employees Fractyl Health Inc. within the market segment - Pharma metabolism
Fractyl Health develops new approaches to treating metabolic diseases like type 2 diabetes by targeting the root cause of the problem in the gut. This chart shows the concentration of unique clinicians and engineers. The proportion of these specialists reflects its pioneering role in the development of procedural therapies for diabetes.
Number of employees in the market segment - Pharma metabolism
Fractyl Health, Inc. is a metabolic therapeutics company developing treatments for type 2 diabetes and obesity. This chart shows overall employment in the metabolic research sector. It illustrates the company's innovative approach to addressing the root causes of disease by targeting the duodenum.
Number of employees in the market as a whole
Fractyl Health develops innovative treatments for type 2 diabetes and obesity based on a procedure that restores the duodenal lining. This is a new approach to metabolic diseases. This graph illustrates the labor market, where companies creating breakthrough medical procedures are hiring physicians, medical engineers, and clinical specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Fractyl Health Inc. (GUTS)
Fractyl Health, Inc. develops innovative treatments for type 2 diabetes and obesity. This chart is a prime example for biotech. The company's very high market cap per employee means investors are pricing in the potential for a breakthrough treatment for a huge market. Value is created by intellectual property, not a large workforce or physical assets.
%20of%20the%20company%20Fractyl%20Health%20Inc.%20(GUTS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Fractyl-Health-Inc.-GUTS&v=1772664680736 "Chart of market capitalization per employee (in thousands of dollars) of the company Fractyl Health Inc. (GUTS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Fractyl Health develops new approaches to treating metabolic diseases such as type 2 diabetes. It is an innovative company at the intersection of medicine and technology. This metric reflects how the market perceives their breakthrough potential. Their high market capitalization per employee reflects investors' belief that their therapy can change the paradigm of chronic disease treatment.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772664680750 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Fractyl Health, Inc. is developing therapies targeting the underlying causes of type 2 diabetes and obesity. It is a biotech company with a breakthrough approach. Its high valuation reflects the company's huge potential market and investors' belief that its treatment approach can change the paradigm for managing metabolic diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772664680758 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Fractyl Health Inc. (GUTS)
Fractyl Health (GUTS) is a company at the intersection of medtech and biotech. They are developing both a device (Rejuva) for treating type 2 diabetes and gene therapy. This is an R&D business. This chart shows the net loss (research and testing costs) per employee working on these two approaches.
%20Chart%20Fractyl%20Health%20Inc.%20(GUTS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Fractyl-Health-Inc.-GUTS&v=1772664680759 "Company Profit Per Employee (in thousands of dollars) Chart Fractyl Health Inc. (GUTS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Fractyl Health is developing new approaches to treating metabolic diseases such as type 2 diabetes. For the company, this clinical development stage represents a future goal. The timeline sets the bar. The success of their therapy could open a huge market and generate profitability per employee significantly above the industry average.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772664680762 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Fractyl Health (GUTS) is developing new treatments for type 2 diabetes and obesity, specifically a procedure that targets the intestinal mucosa. This is R&D in the medical device field. This chart shows that the company is in the development stage. Earnings per employee are negative until the technology is commercialized.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772664680770 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Fractyl Health Inc. (GUTS)
This chart for Fractyl Health, a company developing therapies for metabolic diseases such as type 2 diabetes, shows the commercialization stage. Revenue per employee growth will depend on the success of its innovative procedure aimed at restoring intestinal function.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Fractyl-Health-Inc.-GUTS&v=1772664680773 "Sales chart per company employee Fractyl Health Inc. (GUTS)")
Sales per employee in the market segment - Pharma metabolism
Fractyl Health is a company developing new approaches to treating metabolic diseases (type 2 diabetes) by targeting the gut (Revita). It's an R&D and medical technology company. This metric reflects the average revenue per employee in the segment. It helps assess how productive their team is in commercializing this innovative procedure.
Sales per employee for the market as a whole
Fractyl Health (GUTS) is a company developing innovative treatments for type 2 diabetes and obesity (such as the Revita procedure). They are an R&D company in the commercialization stage. This metric tracks their progress. Increasing revenue per employee (engineer, physician) will signal that their unique therapy is being adopted in clinics.
Short shares by company, segment and market as a whole
Shares shorted by company Fractyl Health Inc. (GUTS)
Fractyl Health is developing innovative treatments for type 2 diabetes and obesity, including a procedural therapy that targets the gut. This is a radical approach in a market dominated by GLP-1 drugs (Ozempic). This chart reflects investor bets that its invasive approach will not be able to compete with the effectiveness and convenience of weekly injections.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Fractyl-Health-Inc.-GUTS&v=1772664680787 "Short Shares Chart for the Company Fractyl Health Inc. (GUTS)")
Shares shorted by market segment - Pharma metabolism
Fractyl Health (GUTS) is a healthcare company developing therapies for metabolic diseases (type 2 diabetes) by targeting the intestinal lining. This chart shows the overall short position in the specialty pharmaceutical sector. It reflects skepticism about their new approach in an era dominated by GLP-1 drugs.
Shares shorted by the overall market
When the market experiences widespread pessimism, as reflected in this chart, companies like Fractyl Health are the first to be hit. Their business relies on lengthy and expensive research into metabolic diseases. During times of fear, investors reduce risk, and "biotech companies of the future" lose capital vital to their research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Fractyl Health Inc. (GUTS)
This chart reflects the swing of sentiment at Fractyl Health. The company is targeting huge markets for metabolic diseases, like type 2 diabetes, with its innovative treatments. This focus triggers sharp swings. When investors believe in the success of its clinical trials, demand pushes the oscillator into overbought territory (above 70). Conversely, the slightest doubt or delay quickly triggers oversold conditions (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Fractyl-Health-Inc.-GUTS&v=1772664680811 "RSI 14 indicator chart for the company's stock Fractyl Health Inc. (GUTS)")
RSI 14 Market Segment - Pharma metabolism
Fractyl Health (GUTS) is a biotech company attacking type 2 diabetes and obesity at the root. Their Revita procedure "reboots" the duodenal lining. The "Pharma Metabolism" sector is the epicenter of the hype. The RSI_14_Seg index for this segment is a barometer of "overheating." It helps us understand: is GUTS's growth driven by their unique approach or is the *entire* sector simply overheated to the limit?
RSI 14 for the overall market
For Fractyl Health, a metabolism R&D company, this chart is a lifeline. During periods of market euphoria, investors are willing to generously fund the "future of medicine" and unprofitable clinical trials. In moments of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GUTS (Fractyl Health Inc.)
Fractyl Health is a company developing innovative treatments for metabolic diseases (type 2 diabetes, obesity). Its approach (Revita) is a procedure that targets the root of the problem in the gut. This chart shows the speculative average price target from analysts based on their belief in this new class of therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GUTS-Fractyl-Health-Inc.&v=1772664680823 "A chart showing analyst consensus forecasts for the expected stock price. GUTS (Fractyl Health Inc.)")
The difference between the consensus estimate and the actual stock price GUTS (Fractyl Health Inc.)
Fractyl Health (GUTS) is a medical technology company developing Revita, a procedure (ablation) to "reset" the intestinal lining to treat type 2 diabetes. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the significant potential analysts see in their non-drug approach.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GUTS-Fractyl-Health-Inc.&v=1772664680834 "A chart showing the difference between the consensus forecast and the actual stock price. GUTS (Fractyl Health Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Fractyl Health is a medical company developing a breakthrough single-step procedure (Revita) for treating type 2 diabetes by "renewing" the intestinal lining. This chart shows the overall expectations for the metabolism sector. It reflects whether experts believe this revolutionary approach compares favorably to medications (GLP-1).
Analysts' consensus forecast for the overall market share price
Fractyl Health is a medical company developing procedural therapies for metabolic diseases. Their method (Revita) is thermal ablation of the intestinal mucosa for the treatment of type 2 diabetes. This chart shows the overall risk appetite. For Fractyl, a company with a breakthrough but invasive technology, overall market optimism is important for funding and convincing physicians and insurers.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Fractyl Health Inc.
Fractyl is a biotech company focused on curing type 2 diabetes, not just managing it. Their approach (RevuIta) is a minimally invasive procedure that renews the duodenal lining to restore metabolism. This graph summarizes their breakthrough R&D, reflecting their clinical progress and their belief in their radically new approach.
AKIMA Market Segment Index - Pharma metabolism
Fractyl Health, Inc. (GUTS) is a metabolic company developing innovative treatments for type 2 diabetes and obesity, including the Revita procedure, which targets the duodenum. The chart shows the segment average index, helping investors assess how Fractyl's breakthrough technology compares to other companies tackling metabolic diseases.
The AKIM Index for the overall market
Fractyl Health is a company developing treatments for metabolic diseases (type 2 diabetes, obesity). Its key technology is Revita (intestinal lining renewal). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative MedTech story compares to overall economic trends.
